Finance ForgeBETA
Crear cuenta gratis
1)Empresas2)Rankings3)Iniciar sesión
Finance Forge Terminal v1.51.3
PrivacidadTérminosCookiesAviso Legal
● Connected
IBIO US Equity
iBio, Inc.
0.78USD▼ 13.44%
Healthcare
Biotechnology
96)Comparar97)Tesis →
Market Cap
$39M
Shares Outstanding
50M
Revenue (TTM)
$100,000
Net Income (TTM)
−$33M
FCF (TTM)
−$24M
— Annual —FY2026
Revenue
$100,000
Operating Margin
-35141.0%
Net Margin
-33044.0%
FCF Margin
-23796.0%
ROE
-38.5%
ROCE
-40.2%
Current Ratio
7.85
FCF / Share
-0.48
Book Value / Share
1.73
IBIO US Equity
0.78USD▼ 13.44%
Tesis →

iBio, Inc. (IBIO): análisis fundamental y valoración

iBio, Inc. cotiza a 0.78 USD y tiene una capitalización bursátil de $39M. En los últimos 12 meses ha facturado $100000 con un margen de flujo de caja libre del -23796.0%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud

Price History
Loading...
Perfil
BolsaNasdaqPaísUnited StatesEmpleados23Beta1.26Web↗ ibioinc.com

iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides a panel of optimized CD3 antibodies that can be paired with tumor-targeting anti…

Múltiplos de Valoración
P/E (Annual)
—
P/E (TTM)
—
P/FCF (Annual)
—
P/FCF (TTM)
—
EV/EBITDA
—
EV/Revenue
—
P/Sales
388.4×
P/Book
0.5×
Rentabilidad (Último Anual)
Gross Margin
—
Operating Margin
-35141.0%
Net Margin
-33044.0%
FCF Margin
-23796.0%
ROE
-38.5%
ROCE
-40.2%
ROA
-33.3%
Effective Tax Rate
0.0%
Métricas TTM
Revenue TTM
$100,000
Gross Profit TTM
—
Operating Income TTM
−$35M
Net Income TTM
−$33M
FCF TTM
−$24M
EPS TTM
-0.32
Quarters Used
4
TTM Period
2025-09-30 → 2026-06-30
Solidez del Balance
Net Debt
—
Net Debt / EBITDA
—
Debt / Equity
—
Current Ratio
7.85
Interest Coverage
—
Working Capital
$80M
Book Value / Share
1.73
Net Debt / Share
—
Crecimiento (YoY)
Revenue YoY
-75.0%
Net Income YoY
-79.8%
FCF YoY
-55.3%
EPS Diluted YoY
+81.7%
Retorno al Accionista
Dividend Yield
—
Payout Ratio
—
FCF / Share
-0.48
CapEx % Revenue
578.0%
Rev / Employee
4,347
Empresas similares
Smart Money
vs Sector: Healthcare (1130 empresas)
MétricaIBIOMediana SectorΔ
Gross Margin—57.0%—
Operating Margin-35141.0%-38.6%-35102.4%
Net Margin-33044.0%-33.6%-33010.4%
FCF Margin-23796.0%-13.9%-23782.1%
ROE-38.5%-40.4%+1.9%
ROA-33.3%-32.0%-1.3%
Current Ratio7.852.84+5.01
Debt / Equity—0.28—
Scoring Fundamental
Capital Allocation
1/ 8Débil
✗FCF+Free cash flow positivo
✗FCFmMargen FCF > 10%
✗DilucSin dilución significativa (< 2%/año en 3 años)
✗Rev↑Revenue CAGR 3 años > 5%
✗ROCERetorno sobre capital empleado > 10%
✗DeudaDeuda neta/EBITDA < 3× (o posición de caja neta)
✗Mg↑Margen operativo ≥ hace 2-3 años (tolerancia -2pp)
✓Inv.R&D + Capex > 3% de revenue (reinversión en el negocio)